Purpose: Automatic liver segmentation from abdominal computed tomography (CT) images is a fundamental task in computer-assisted liver surgery programs. Many liver segmentation algorithms are very sensitive to fuzzy boundaries and heterogeneous pathologies, especially when the data are scarce. To solve these problems, we propose an automatic liver segmentation framework based on three-dimensional (3D) convolutional neural networks with a hybrid loss function.
Methods: Two networks are incorporated in our method with the first being a liver shape autoencoder that is trained to obtain compressed codes of liver shapes, and the second being a liver segmentation network that is trained with a hybrid loss function. The design of the hybrid loss function is comprised of three parts. The first part is an adaptively weighted cross-entropy loss, which pays more attention to misclassified pixels. The second part is an edge-preserving smoothness loss, which guarantees that the adjacent pixels with the same label have similar outputs, while dissimilar for pixels with different labels. The third part of the loss is a shape constraint to model high-level structural differences based on the learned shape codes. Both networks use 3D operations for data processing. In our experiments, data augmentation is performed at both the training and the test stage.
Results: We extensively evaluated our method on two datasets: the Segmentation of the Liver Competition 2007 (Sliver07), and the Combined (CT-MR) Healthy Abdominal Organ Segmentation (CHAOS) Challenge. Finally, with only 20 training scans, we achieved the best score of 82.55 on the Sliver07 challenge, and a score of 83.02 on the CHAOS challenge.
Conclusions: In this study, we proposed a novel hybrid loss to overcome the difficulties in liver segmentation. The quantitative and qualitative results demonstrate that our method is highly suited for pathological liver segmentation, even when trained with a small dataset.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mp.14732 | DOI Listing |
Arq Bras Cir Dig
January 2025
Mongi Slim Hospital, Department of Pathology - Marsa, Tuni, Tunísia.
Background: Hepatocellular carcinoma (HCC) encompasses rare variants like chromophobe hepatocellular carcinoma (CHCC) characterized by distinct histological features and molecular profiles.
Case Report: A 56-year-old male with chronic hepatitis C, presenting pain in the right hypochondrium. Imaging revealed a solitary liver lesion, subsequently resected and histologically diagnosed as HCC.
Quant Imaging Med Surg
January 2025
Department of Radiology, West China Hospital of Sichuan University, Chengdu, China.
BMC Cancer
January 2025
Department of Radiology, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology), No. 79 Kangning Road, Zhuhai, 519000, Guangdong Province, China.
Background: Besides tumorous information, synergistic liver parenchyma assessments may provide additional insights into the prognosis of hepatocellular carcinoma (HCC). This study aimed to investigate whether 3D synergistic tumor-liver analysis could improve the prediction accuracy for HCC prognosis.
Methods: A total of 422 HCC patients from six centers were included.
Front Oncol
January 2025
Department of Radiology, Ordos Central Hospital, Ordos, Inner Mongolia, China.
Background: Improvements in the clinical diagnostic use of magnetic resonance imaging (MRI) for the identification of liver disorders have been made possible by gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA). Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) technology is in high demand.
Objectives: The purpose of the study is to segment the liver using an enhanced multi-gradient deep convolution neural network (EMGDCNN) and to identify and categorize a localized liver lesion using a Gd-EOB-DTPA-enhanced MRI.
Radiol Adv
January 2025
Department of Radiology, Duke University Medical Center, Durham, NC 27710, United States.
Purpose: To assess agreement between CT volumetry change classifications derived from Quantitative Imaging Biomarker Alliance Profile cut-points (ie, QIBA CTvol classifications) and the Response Evaluation Criteria in Solid Tumors (RECIST) categories.
Materials And Methods: Target lesions in lung, liver, and lymph nodes were randomly chosen from patients in 10 historical clinical trials for various cancers, ensuring a balanced representation of lesion types, diameter ranges described in the QIBA Profile, and variations in change magnitudes. Three radiologists independently segmented these lesions at baseline and follow-up scans using 2 software tools.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!